|
Market Closed -
Sao Paulo
03:53:48 2026-11-11 pm EST
|
5-day change | 1st Jan Change | ||
| 93.24 BRL | +15.54% |
|
-0.58% | +41.36% |
| 09:00am | Amgen's Sjogren's drug cuts disease activity in trial | RE |
| 08:56am | Amgen Potential Autoimmune Drug Meets Primary Endpoint in Late-Stage Study | MT |
| Market Cap | 252B 1,400B 227B 210B 189B 358B 23,602B 367B 2,511B 1,001B 12,641B 944B 924B 40,226B | P/E 2026 * |
24x | P/E 2027 * | 22.9x |
|---|---|---|---|---|---|
| Enterprise Value | 291B 1,619B 262B 242B 219B 414B 27,294B 425B 2,904B 1,157B 14,618B 1,092B 1,069B 46,518B | EV / Sales 2026 * |
7.37x | EV / Sales 2027 * | 6.91x |
| Free-Float |
99.77% | Yield 2026 * |
2.17% | Yield 2027 * | 2.29% |
Last Transcript: Amgen Inc.
| 1 day | +15.54% | ||
| 1 week | -0.58% | ||
| Current month | +2.27% | ||
| 1 month | +25.32% | ||
| 3 months | +21.55% | ||
| 6 months | +62.52% | ||
| Current year | +41.36% |
| 1 week | 88.18 |  | 94.72 |
| 1 month | 73.99 | | 94.72 |
| Current year | 48.4 | | 94.72 |
| 1 year | 48.4 | | 94.72 |
| 3 years | 45.12 | | 94.72 |
| 5 years | 37.52 | | 94.72 |
| 10 years | 17.15 | | 94.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
| Director of Finance/CFO | 62 | 2010-05-12 | |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 57 | 2023-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +15.54% | -0.58% | - | - | 252B | |
| +0.35% | +1.36% | +45.38% | +134.58% | 1,276B | |
| -0.13% | +1.48% | +44.67% | +89.94% | 676B | |
| +0.37% | +0.05% | +31.00% | +112.77% | 519B | |
| +0.02% | +2.79% | +44.10% | +69.76% | 388B | |
| -0.59% | -2.11% | +61.83% | +43.63% | 365B | |
| -1.29% | +0.94% | +29.88% | +58.29% | 307B | |
| +0.09% | +0.99% | +5.87% | +37.72% | 287B | |
| +0.62% | -2.17% | +38.31% | +75.53% | 252B | |
| -0.67% | -2.72% | +38.49% | +126.52% | 212B | |
| Average | +1.43% | +2.34% | +37.73% | +83.19% | 476B | |
| Weighted average by Cap. | +0.79% | +2.51% | +40.29% | +95.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 39.47B 220B 35.58B 32.87B 29.71B 56.22B 3,702B 57.61B 394B 157B 1,983B 148B 145B 6,310B | 41.29B 230B 37.21B 34.38B 31.08B 58.8B 3,873B 60.25B 412B 164B 2,074B 155B 152B 6,600B |
| Net income | 10.52B 58.54B 9.48B 8.76B 7.92B 14.98B 987B 15.35B 105B 41.85B 528B 39.48B 38.65B 1,682B | 11.03B 61.36B 9.94B 9.18B 8.3B 15.7B 1,034B 16.09B 110B 43.86B 554B 41.39B 40.51B 1,763B |
| Net Debt | 39.36B 219B 35.48B 32.78B 29.63B 56.06B 3,692B 57.44B 393B 157B 1,977B 148B 145B 6,292B | 33.8B 188B 30.46B 28.15B 25.44B 48.14B 3,170B 49.32B 337B 134B 1,698B 127B 124B 5,403B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-11 | R$93.24 | +15.54% | 5,855 |
| 26-11-10 | R$93.16 | +1.38% | 6 |
| 26-11-09 | R$91.89 | +0.89% | 32 |
| 26-11-06 | R$91.08 | +0.20% | 270 |
| 26-11-05 | R$90.90 | -3.07% | 273 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
